L2IP - Instituto de Pesquisas Clinicas Ltda.
Welcome,         Profile    Billing    Logout  
 0 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Campos, Luciana Teixeira de
ABX464-106, NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Recruiting
3
612
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Active, not recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
COMMIT-CD, NCT06937099: Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Not yet recruiting
3
290
Europe, Canada, US, RoW
Mirikizumab, LY3074828, Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Crohn's Disease, Obesity or Overweight
05/28
05/28
COMMIT-UC, NCT06937086: Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Not yet recruiting
3
350
Europe, Canada, US, RoW
Mirikizumab, LY3074828, Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Ulcerative Colitis, Obesity or Overweight
04/28
04/28
NCT05298657: The Angiotensin-Melatonin Axis in Poor and Hyper Responders for IVF Treatment

Not yet recruiting
N/A
200
RoW
Fatima College of Health Sciences, ART Fertility Clinics LLC
Poor Response to Ovulation Induction, PCOS, Endometriosis, Infertility, Female
08/24
08/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Campos, Luciana Teixeira de
ABX464-106, NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Recruiting
3
612
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Active, not recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
COMMIT-CD, NCT06937099: Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Not yet recruiting
3
290
Europe, Canada, US, RoW
Mirikizumab, LY3074828, Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Crohn's Disease, Obesity or Overweight
05/28
05/28
COMMIT-UC, NCT06937086: Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Not yet recruiting
3
350
Europe, Canada, US, RoW
Mirikizumab, LY3074828, Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Ulcerative Colitis, Obesity or Overweight
04/28
04/28
NCT05298657: The Angiotensin-Melatonin Axis in Poor and Hyper Responders for IVF Treatment

Not yet recruiting
N/A
200
RoW
Fatima College of Health Sciences, ART Fertility Clinics LLC
Poor Response to Ovulation Induction, PCOS, Endometriosis, Infertility, Female
08/24
08/24

Download Options